Robert P. Mauch, President and CEO of Cencora, expressed enthusiasm about the acquisition, highlighting EyeSouth's commitment to empowering ophthalmologists and delivering exceptional patient care. He stated, "By joining RCA, these physicians will become part of an organization with capabilities designed to provide world-class retina care and be supported by Cencora’s longstanding commitment to community physicians."
The acquisition is anticipated to be slightly accretive to Cencora's adjusted diluted earnings per share (EPS) within the first twelve months post-transaction, net of financing costs. However, it is important to note that the transaction is subject to customary closing conditions, including the necessary regulatory approvals. Cencora has reaffirmed its fiscal 2026 financial guidance, which does not currently account for the transaction's closing within this fiscal year.
This acquisition aligns with Cencora's strategic objectives to enhance its service offerings and expand its market presence in the healthcare sector. The integration of EyeSouth's retina business is expected to create synergies that will benefit both organizations and their patients, ultimately advancing the fight against blindness through innovative treatments and clinical trials. The collaboration is seen as a significant step forward in Cencora's mission to improve patient outcomes and solidify its position as a leader in pharmaceutical solutions.
